Healthcare · Profile from Healthcare Research Companion
Quest Diagnostics Incorporated
America's largest independent clinical laboratory by test volume and, in clinical diagnostics alone, by revenue (Labcorp is larger in total revenue only because of its drug-development lab business), built from a New York lab founded in 1967 and spun off from Corning in 1996. Quest runs a national network of labs, couriers and ~2,000+ patient service centres and serves roughly a third of US adults each year. Its history is a lesson in the economics of scale testing: acquisitions that consolidated a fragmented industry, a decade locked out of UnitedHealthcare's network, Medicare price cuts under PAMA, a pandemic windfall that came and went, and since 2023 a strategy of buying hospital outreach labs and running hospital labs under joint ventures.
At a glance
- Founded
- 1967, New York City, as MetPath, by Dr. Paul A. Brown; acquired by Corning in 1982; spun off as Quest Diagnostics on 31 December 1996
- Founder
- Paul A. Brown (MetPath)
- Headquarters
- Secaucus, New Jersey (since 2014; previously Madison, New Jersey)
- Ownership / structure
- Public company, NYSE: DGX (since 1996 spin-off); S&P 500
- Leadership (2026)
- Jim Davis, chairman, CEO and president (CEO since November 2022); Sam Samad, CFO (since July 2022, formerly CFO of Illumina)
- Segment and buyer
- Diagnostics and lab testing: routine, advanced (genetic, oncology, neurology), anatomic pathology, employer drug testing and consumer-initiated testing, plus hospital lab management. Customers are physicians, hospitals, health plans, employers and consumers; payers are commercial health plans (~half of revenue), Medicare and Medicaid, patients and clients billed directly
- Scale
- 2025 revenue $11.04bn (+11.8%); reported EPS $8.75, adjusted EPS $9.85 (reported). Q3 2026 revenue $3.10bn (+10.0%); 2026 guidance raised in October to $12.065–12.105bn revenue and adjusted EPS $11.25–11.35 (reported). Nearly 57,000 employees (company, early 2026)
- Capital / market cap
- Self-funded; investment-grade debt; market cap roughly $18–22bn in 2025–26 (verify current level)
- Signature moves (incl. failures)
- Corning spin-off (1996); SmithKline Beecham Clinical Laboratories (1999); loss of UnitedHealthcare to Labcorp (2007–17); Nichols Institute Diagnostics guilty plea and $302m settlement (2009); consumer-initiated testing (QuestDirect, 2018); AMCA billing-vendor breach (2019); COVID-19 testing surge and fall (2020–23); outreach acquisitions, LifeLabs and the Corewell joint venture (2023–26)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1996
Corning Spin Off
Spin-off
1999
SmithKline Beecham Clinical Labs
Acquisition
2007
Loss of UnitedHealthcare Contract
Payer contract loss (failure) and recovery
2009
Nichols Institute Settlement
Regulatory settlement / guilty plea
2018
QuestDirect Consumer Testing
Launch / consumer channel
2019
AMCA Data Breach
Data breach (vendor)
2020
Covid Testing Surge
Demand shock / capacity build
2024
Outreach Acquisitions LifeLabs and Corewell
Acquisitions / joint venture